Serono Genetics Institute S.a.

Genset S.a.

Institut National De La Sante Et De La Recherche Medicale

Genset

Other

Frances Yen-Potin

Bernard Bihain

Lydie Bougueleret

Mary Erickson

Joachim Fruebis

Blake Denison

Jean-Baptiste Dumas Milne Edwards

Hiroaki Tanaka

Aymeric Duclert

Stephane Bejanin

Severin Jobert

Jean-Yves Giordano

Catherine Clusel

Barbara A Chicca

Barbara Bour

John Chicca

Dana Ebbets-Reed

Luisa Salter-Cid

The present invention relates to antibodies specific for a receptor termed the Lipolysis Stimulated Receptor (LSR). Compositions comprising the antibodies are also provided.

Lipolysis stimulated receptor (LSR) specific antibodies

The present invention relates to the field of obesity research. Obesity is a public health problem that is serious and widespread. The application is related to OBG3 polypepide fragments and compositions comprising these fragments. It also discloses methods of reducing free fatty acid levels with the polypeptide fragments of the invention.

OBG3 globular head and uses thereof

The present invention relates to the field of obesity research. Obesity is a public health problem that is serious and widespread. This application pertains to nucleic acids encoding a compound, globular OBG3 polypeptide fragments, vectors and transformed host cells containing these nucleic acids and methods of making the globular OBG3 polypeptide fragments.

Nucleic acids encoding OBG3 polypeptides

The present invention relates to the field of obesity research. Obesity is a public health problem that is serious and widespread. A compound, globular OBG3, has been identified that reduces weight gain in animals. This compound should be effective for reducing body mass and for treating obesity-related diseases and disorders. These obesity-related diseases and disorders include hyperlipidemias, atherosclerosis, diabetes, and hypertension.

Nucleic acids encoding OBG3 globular head and uses thereof

The present invention relates to a new complex receptor polypeptide LSR (Lipolysis Stimulated Receptor), characterized by its functional activities, the cloning of the cDNAs complementary to the messenger RNAs encoding each of the subunits of the multimeric complex, vectors and transformed cells, methods of diagnosis and of selection of compounds which can be used as medicament for the prevention and/or treatment of pathologies and/or of pathogeneses such as obesity and anorexia, hyperlipidemias, atherosclerosis, diabetes, hypertension, and more generally the various pathologies associated with abnormalities in the metabolism of cytokines.

LSR receptor, its activity, its cloning, and its applications to the diagnosis, prevention and/or treatment of obesity and related risks or complications

The present invention relates to the field of metabolic research. Metabolic disorders, such as obesity, are a public health problem that is serious and widespread. GSSP4 polypeptides have been identified that are believed to be beneficial in the treatment of metabolic disorders. These compounds should be effective for reducing cholesterol levels, body mass, body fat, and for treating metabolic-related diseases and disorders. The metabolic-related diseases or disorders include, but are not limited to, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, diabetes, glucose intolerance, insulin resistance and hypertension.

GSSP4 polynucleotides and polypeptides and uses thereof

Methods and pharmaceutical compositions useful for treating obesity-related disorders using ApM-1 and related proteins.

Lipoprotein-regulating medicants

The invention provides the genomic sequence of GSSP-2, GSSP-2 cDNAs and GSSP-2 polypeptides. Further the invention provides polynucleotides including biallelic markers derived from the GSSP-2 gene and from genomic regions flanking the gene. This invention also provides polynucleotides and methods suitable for genotyping a nucleic acid molecule containing sample for one or more biallelic markers of the invention. Further, the invention provides methods to detect a statistical correlation between a biallelic marker allele and a phenotype and/or between a biallelic marker haplotype and a phenotype. The invention also concerns methods and compositions for killing neoplastic cells or inhibiting neoplastic cell growth. In particular, the present invention concerns cell proliferation arresting/inhibiting and apoptosis/necrosis inducing compositions and methods for the treatment of tumors. The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides.

Methods and compositions for inhibiting neoplastic cell growth

Methods and pharmaceutical compositions useful for modulating lipoprotein levels in vivo. The invention stems from the discovery that activity of the Lipolysis Stimulated Receptor (LSR) can be inhibited or enhanced by exogenous agents, including polypeptides.

Lipoprotein-regulating medicaments

LSR receptor, activity, cloning, and uses for diagnosing, preventing and/or treating obesity and related risks or complications

The invention provides novel APM1 genomic sequences, polypeptides, antibodies, and polynucleotides including biallelic markers derived from the APM1 locus. Primers hybridizing to regions flanking these biallelic markers are also provided. This invention also provides polynucleotides and methods suitable for genotyping a nucleic acid containing sample for one or more biallelic markers of the invention. Additionally, the invention provides methods to detect a statistical correlation between a biallelic marker allele and a phenotype and/or between a biallelic marker haplotype and a phenotype. Further, the invention provides diagnostic methods for early detection of obesity-related disorders.

Growing community of inventors

Vandoeuvre-les-Nancy, France

Frances Yen-Potin